Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same author

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026
Same author

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Cancer·2026
Same author

Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis.

The American journal of cardiology·2026

Related Experiment Video

Updated: Jan 9, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.9K

Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia.

Binsah George1, Manu Pandey2, Jacob Herstein3

  • 1Department of Hematology-Oncology, University of Texas Health Science Center at Houston.

American Journal of Clinical Oncology
|December 3, 2025
PubMed
Summary

Natural killer (NK) cells show promise in fighting acute myeloid leukemia (AML) by enhancing the immune system. Research explores harnessing NK cell therapy to overcome treatment resistance and improve patient outcomes in AML.

Keywords:
acute myeloid leukemiaimmunotherapynatural killer cellular therapy

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.7K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

6.3K

Related Experiment Videos

Last Updated: Jan 9, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.9K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.7K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

6.3K

Area of Science:

  • Hematologic Oncology
  • Immunology
  • Innate Immunity

Background:

  • Acute myeloid leukemia (AML) presents significant challenges in treatment due to genetic complexity and therapy resistance.
  • Standard treatments like chemotherapy and stem cell transplantation (HSCT) have limitations, leaving many patients with unsatisfactory outcomes.
  • Immunotherapy offers a promising avenue to enhance anti-leukemia responses by leveraging the patient's immune system.

Purpose of the Study:

  • To review the role of Natural Killer (NK) cells in acute myeloid leukemia (AML) immune surveillance.
  • To elucidate mechanisms of NK cell dysfunction in AML.
  • To discuss current and future therapeutic strategies utilizing NK cells for AML management.

Main Methods:

  • Review of existing literature on NK cell function in AML.
  • Analysis of mechanisms underlying NK cell impairment in the context of AML.
  • Examination of current and emerging NK cell-based immunotherapies for AML.

Main Results:

  • NK cells possess inherent capabilities to eliminate AML cells directly.
  • NK cell function is often compromised in patients with AML, hindering effective anti-leukemia immunity.
  • Various strategies are being developed to enhance NK cell activity and overcome immune evasion in AML.

Conclusions:

  • NK cell-based immunotherapies represent a significant potential advancement in AML treatment.
  • Addressing NK cell dysfunction and immune escape is crucial for improving treatment efficacy and durability.
  • Further research is vital to optimize NK cell therapies for personalized AML treatment approaches.